No participation yet
- Joined Aug 2021
Due to a lack of conclusive treatment and an advanced diagnostic procedure, the global primary biliary cholangitis treatment market is expected to be driven by a high unmet medical need, as well as increasing awareness among healthcare professionals and patients alike. Primary biliary cholangitis incidence and prevalence differ by area, ranging from 0.7 to 49 and 6.7 to 402 per million, respectively. The rising incidence and prevalence of the disease, as well as increased exposure to immune system causes such as pesticides, are currently driving revenue growth in the primary biliary cholangitis treatment market. Furthermore, over the projected era, lifestyle changes such as smoking, alcoholism, and obesity are expected to drive the demand for primary biliary cholangitis care.